Ajanta Pharma Ltd. News and Updates

Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news on Ajanta Pharma Ltd. from all sources in a single place.

Load latest

Ajanta Pharma Ltd.

21 Sep 2020

2596.75

-1.00%

Ajanta Pharma (BUY): NDR takeaways Earnings drivers tracking well

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

We hosted investor meetings with the management of Ajanta Pharma (AJP).

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

03 Aug 2020

2596.75

-1.00%

Buy Ajanta Pharmaceuticals; target of Rs 1810: ICICI Direct

Moneycontrol

ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1810 in its research report dated July 31, 2020.

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

31 Jul 2020, 09:33AM

2596.75

-1.00%

Ajanta Pharma Standalone June 2020 Net Sales at Rs 560.85 crore, up 2.77% Y-o-Y

Moneycontrol

NULL

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Q1 profit up 29% at Rs 148 crore

Moneycontrol | 30 Jul 2020, 04:35PM 1 more

Ajanta Pharma Ltd.

31 Jul 2020, 12:00AM

2596.75

-1.00%

US/Asia businesses drive superior performance

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

EBITDA margin expanded at higher rate of 590bp YoY with superior product mix and controlled opex. We remain positive on AJP on its new launches, rising share in key markets of the US/India/Asia/Africa and improved operating leverage. Re-iterate In the branded formulation segment, AJP witnessed 15% YoY decline in India, while it delivered 27.8%/17.4% YoY growth in Asia/Africa in 1QFY21. AJP has strong pipeline of registration in both Asia/Africa branded segment. We expect Africa branded segment to deliver better 12% CAGR over FY20-22E to INR4.3b owing to increased offerings and better reach. AJPs US sales grew 46% YoY due to increased traction in existing With 19 ANDAs pending approval, the company has an intention to file 10-12 ANDAs annually. Considering 6-7 launches in FY21, we expect AJP to garner 20% CAGR in US sales over FY20-22E to INR7.3b in this segment.

Ajanta Pharma Ltd.'s price crossed above 50Day SMA today

Ajanta Pharma Ltd.

31 Jul 2020, 12:00AM

2596.75

-1.00%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations - Focus on new launches, few therapies Domestic formulations comprise 30% of FY20 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~11% CAGR in...

Ajanta Pharma Ltd.'s price crossed above 50Day SMA today

Ajanta Pharma Ltd.

30 Jul 2020

2596.75

-1.00%

Ajanta Pharma (BUY): Solid beat on margins set to normalise in coming quarters

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) posted Q1 revenue/EBITDA growth of 9%/33% YoY to Rs 6.7bn/Rs 2.2bn.

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

18 Jul 2020

2596.75

-1.00%

Pharma stocks in focus! Lupin, Ajanta Pharma are on next leg of upside: Umesh Mehta

Moneycontrol

Pharma stocks have witnessed a brief halt/pullback towards short term moving averages, however, the trend is still positive. Some of the players have started their next up leg.

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

25 May 2020

2596.75

-1.00%

Buy Ajanta Pharmaceuticals; target of Rs 1730: ICICI Direct

Moneycontrol

ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated May 22, 2020.

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

22 May 2020

2596.75

-1.00%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations: Focus on new launches, few therapies Domestic formulations comprise 30% of FY20 revenues. Main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to higher competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

21 May 2020

2596.75

-1.00%

Buy Ajanta Pharma; target of Rs 1700: Motilal Oswal

Moneycontrol

Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 1700 in its research report dated May 20, 2020.